SCA
UTHR icon

Secor Capital Advisors’s United Therapeutics UTHR Stock Holding History

Secor Capital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-25,640
Closed -$3M – 594
2017
Q3 		$3M Buy
+25,640
New +$3.27M 0.29% 117
2016
Q2 		– Sell
-10,698
Closed -$1.19M – 711
2016
Q1 		$1.19M Buy
10,698
+7,552
+240% +$956K 0.16% 127
2015
Q4 		$493K Buy
+3,146
New +$458K 0.14% 249

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Secor Capital Advisors's UTHR Position: Q4 2017 in Review

Secor Capital Advisors sold out of United Therapeutics (UTHR) in Q4 2017, closing a stake of 25,640 shares — an estimated $3M sold.

Secor Capital Advisors first reported a position in UTHR in Q4 2015 and held it in 3 quarters. The position peaked at $3M in Q3 2017. 400 funds tracked by Wall St. Rank hold UTHR as of Q4 2017.

  • Secor Capital Advisors reported no remaining United Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Secor Capital Advisors sold 25,640 United Therapeutics shares in Q4 2017, an estimated $3M.
  • Secor Capital Advisors first reported a position in United Therapeutics in Q4 2015 and held it in 3 quarters.
  • Secor Capital Advisors's United Therapeutics position peaked at $3M in Q3 2017.
  • 400 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2017.

Based on Secor Capital Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.